Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) is warning consumers that several products promoted and sold for weight loss have been found to contain undeclared ingredients and should not be purchased or used.
Laboratory analysis has confirmed the presence of these undeclared ingredients in the following products:
- Mezo (benzylsibutramine)
- LX1 (DMAA)
- Best Line Suplemento Alimenticio Capsules (sibutramine)
Benzylsibutramine is structurally similar to sibutramine, a controlled substance that was removed from the market in 2010 due to safety concerns. Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may pose a significant risk in patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. DMAA (1,3-dimethylamylamine, methylhexanamine) also known as geranium extract, is commonly used as a stimulant, pre-workout, and weight loss ingredient in supplements. This ingredient can be harmful as it can narrow blood vessels and arteries, which can increase blood pressure or other cardiovascular problems (eg, shortness of breath, arrhythmias, tightening in the chest, heart attack).
RELATED: More Safety Alerts and Recalls
These products are sold nationwide through various distribution channels, including the internet and retail stores. The FDA recommends that consumers discontinue and discard these supplements immediately.
For more information call (855) 543-3784 or visit the FDA Safety Alert Page.
